Is HAE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HAE. It does not provide personalized investment advice.

HAE (Haemonetics Corporation) Stock Analysis - Financials

Haemonetics Corporation (HAE) is a publicly traded Healthcare sector company. As of November 5, 2026, HAE trades at $127.52 with a market cap of $5.47B and a P/E ratio of 56.94. HAE moved +0.08% today. Year to date, HAE is +55.20%; over the trailing twelve months it is +152.94%. Its 52-week range spans $47.32 to $128.77. Analyst consensus is strong buy with an average price target of $125.38. Rallies surfaces HAE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are HAE's key financials?

HAE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. HAE recently traded at $127.52. Market cap is $5.47B. P/E ratio is 56.94. Revenue is $1.35B.

HAE Key Metrics

Key financial metrics for HAE
Metric	Value
Price	$127.52
Market Cap	$5.47B
P/E Ratio	56.94
EPS	$2.09
Dividend Yield	0.00%
52-Week High	$128.77
52-Week Low	$47.32
Volume	125
Avg Volume	0
Revenue (TTM)	$1.35B
Net Income	$96.29M
Gross Margin	59.03%

HAE Analyst Consensus

9 analysts cover HAE: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $125.38.

Common questions about HAE

What are HAE's key financials?: HAE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. HAE recently traded at $127.52. Market cap is $5.47B. P/E ratio is 56.94. Revenue is $1.35B.
Is HAE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HAE. It does not provide personalized investment advice.